NASDAQ:REPL Replimune Group (REPL) Stock Price, News & Analysis $10.35 -0.13 (-1.24%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$10.27▼$10.6050-Day Range$5.01▼$11.0652-Week Range$4.92▼$21.63Volume623,955 shsAverage Volume701,742 shsMarket Capitalization$707.11 millionP/E RatioN/ADividend YieldN/APrice Target$16.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Replimune Group alerts: Email Address Replimune Group MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside61.0% Upside$16.67 Price TargetShort InterestBearish8.74% of Shares Sold ShortDividend StrengthN/ASustainability-1.28Upright™ Environmental ScoreNews Sentiment1.24Based on 3 Articles This WeekInsider TradingSelling Shares$712,516 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($3.31) to ($2.60) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.45 out of 5 starsMedical Sector121st out of 936 stocksBiological Products, Except Diagnostic Industry11th out of 154 stocks 3.5 Analyst's Opinion Consensus RatingReplimune Group has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageReplimune Group has only been the subject of 3 research reports in the past 90 days.Read more about Replimune Group's stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted8.74% of the outstanding shares of Replimune Group have been sold short.Short Interest Ratio / Days to CoverReplimune Group has a short interest ratio ("days to cover") of 5.1.Change versus previous monthShort interest in Replimune Group has recently increased by 4.01%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldReplimune Group does not currently pay a dividend.Dividend GrowthReplimune Group does not have a long track record of dividend growth. Previous Next 4.5 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreReplimune Group has received a 69.41% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services for cancer" product. See details.Environmental SustainabilityThe Environmental Impact score for Replimune Group is -1.28. Previous Next 3.5 News and Social Media Coverage News SentimentReplimune Group has a news sentiment score of 1.24. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.62 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Replimune Group this week, compared to 2 articles on an average week.Search Interest6 people have searched for REPL on MarketBeat in the last 30 days. This is an increase of 500% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Replimune Group to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Replimune Group insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $712,516.00 in company stock.Percentage Held by Insiders20.60% of the stock of Replimune Group is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions92.53% of the stock of Replimune Group is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Replimune Group's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Replimune Group are expected to grow in the coming year, from ($3.31) to ($2.60) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Replimune Group is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Replimune Group is -3.19, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioReplimune Group has a P/B Ratio of 1.70. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Replimune Group's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all $20,000 of his wife's 401k into shares of just ONE stock. Everyone on Wall Street said he was crazy. But a year later, that $20,000 in his wife's account was worth $120,000. Today, he says: "If you thought the dot-com mania was intense, what's about to happen in the coming weeks could be even crazier and could open up a new window of opportunity for 500%-plus gains."Click here now to watch this exclusive interview About Replimune Group Stock (NASDAQ:REPL)Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma. The company is also developing RP2, which is in Phase I clinical trials to express an anti-CTLA-4 antibody-like protein to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trial to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.Read More REPL Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart REPL Stock News HeadlinesJune 7, 2024 | globenewswire.comReplimune to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceJune 6, 2024 | globenewswire.comReplimune Announces Positive Topline Primary Analysis Data by Independent Central Review from IGNYTE Clinical Trial of RP1 plus Nivolumab in Anti-PD1 Failed MelanomaJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.June 3, 2024 | globenewswire.comReplimune Presents Positive Data from RP1 and RP2 Clinical Programs at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 23, 2024 | globenewswire.comReplimune to Present at the 2024 American Society of Clinical Oncology (ASCO) Annual MeetingMay 22, 2024 | seekingalpha.comReplimune: Continuing To Justify The Bear Thesis (For Now)May 20, 2024 | markets.businessinsider.comBuy Rating Affirmed: Replimune’s Financial Stability and RP1’s Promising FutureMay 17, 2024 | markets.businessinsider.comBuy Rating Affirmed on Replimune Group Amidst Promising RP1 Developments and Strong Financial PositionJuly 27, 2024 | The Oxford Club (Ad)Man Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.May 17, 2024 | markets.businessinsider.comBuy Recommendation for Replimune Group Based on Promising RP1 Clinical Developments and Robust Financial OutlookMay 16, 2024 | investorplace.comREPL Stock Earnings: Replimune Group Misses EPS for Q4 2024May 16, 2024 | globenewswire.comReplimune Reports Fiscal Fourth Quarter and Year Ended 2024 Financial Results and Provides Corporate UpdateApril 7, 2024 | globenewswire.comInterim Results from the ARTACUS Clinical Trial of RP1 Monotherapy in Solid Organ and Hematopoietic Cell Transplant Recipients with Skin Cancers Presented During Oral Presentation at the American Association of Cancer Research (AACR) 2024 Annual MeetingApril 4, 2024 | globenewswire.comReplimune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)March 30, 2024 | bizjournals.comFive things: Downtown building sale, nursing home lawsuit, Fast 50 and the clock is tickingMarch 29, 2024 | uk.investing.comReplimune appoints new CEO ahead of drug applicationMarch 28, 2024 | bizjournals.comPetri Dish: NIH sends BioNTech notice of default; Intellia ends Regeneron dealMarch 26, 2024 | marketwatch.comReplimune Names Sushil Patel as CEO in Broader ShakeupSee More Headlines Receive REPL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Replimune Group and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/16/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End3/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:REPL CUSIPN/A CIK1737953 Webwww.replimune.com Phone(781) 222-9600FaxN/AEmployees210Year Founded2015Price Target and Rating Average Stock Price Target$16.67 High Stock Price Target$17.00 Low Stock Price Target$16.00 Potential Upside/Downside+61.0%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($3.24) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-215,790,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-48.62% Return on Assets-39.47% Debt Debt-to-Equity Ratio0.18 Current Ratio10.72 Quick Ratio10.72 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$6.10 per share Price / Book1.70Miscellaneous Outstanding Shares68,320,000Free Float48,764,000Market Cap$707.11 million OptionableOptionable Beta1.25 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Philip Astley-Sparke F.S.A. (Age 53)CEO & Director Comp: $1.07MDr. Sushil Patel Ph.D. (Age 53)Chief Strategy Officer Comp: $665.05kDr. Robert Coffin Ph.D. (Age 59)Founder, President, Chief Research & Development Officer and Director Comp: $785.89kMs. Emily Luisa Hill (Age 44)Chief Financial Officer Dr. Colin A. Love Ph.D. (Age 66)Chief Operating Officer Comp: $419.37kMr. Andrew Schwendenman (Age 48)Chief Accounting Officer & Treasurer Dr. Pamela Esposito Ph.D. (Age 50)Chief Business Officer Comp: $464.63kMs. Tanya N. Lewis M.S. (Age 53)Chief Development Operations Officer Comp: $4.7kMr. Christopher Sarchi (Age 56)Chief Commercial Officer Dr. Konstantinos Xynos M.B.A. (Age 58)M.D., Ph.D., Chief Medical Officer More ExecutivesKey Competitorsbluebird bioNASDAQ:BLUEAlloVirNASDAQ:ALVRAtara BiotherapeuticsNASDAQ:ATRAVir BiotechnologyNASDAQ:VIRAmneal PharmaceuticalsNASDAQ:AMRXView All CompetitorsInsiders & InstitutionsBank of New York Mellon CorpBought 17,471 shares on 7/26/2024Ownership: 0.264%Nisa Investment Advisors LLCBought 4,946 shares on 7/20/2024Ownership: 0.008%Konstantinos XynosSold 15,881 sharesTotal: $119,107.50 ($7.50/share)Walleye Trading LLCSold 800 shares on 5/17/2024Ownership: 0.000%Robert CoffinSold 11,464 sharesTotal: $74,172.08 ($6.47/share)View All Insider TransactionsView All Institutional Transactions REPL Stock Analysis - Frequently Asked Questions How have REPL shares performed this year? Replimune Group's stock was trading at $8.43 on January 1st, 2024. Since then, REPL shares have increased by 22.8% and is now trading at $10.35. View the best growth stocks for 2024 here. How were Replimune Group's earnings last quarter? Replimune Group, Inc. (NASDAQ:REPL) released its quarterly earnings data on Thursday, May, 16th. The company reported ($0.82) EPS for the quarter, beating analysts' consensus estimates of ($0.86) by $0.04. When did Replimune Group IPO? Replimune Group (REPL) raised $100 million in an initial public offering on Friday, July 20th 2018. The company issued 6,700,000 shares at $14.00-$16.00 per share. J.P. Morgan, Leerink Partners and BMO Capital Markets served as the underwriters for the IPO. Who are Replimune Group's major shareholders? Top institutional investors of Replimune Group include Bank of New York Mellon Corp (0.26%) and Nisa Investment Advisors LLC (0.01%). Insiders that own company stock include Robert Coffin, Philip Astley-Sparke, Colin Love, Pamela Esposito, Sushil Patel, Tanya Lewis, Jean M Franchi, Konstantinos Xynos, Christopher Sarchi, Andrew Schwendenman and Fund Iv LP Omega. View institutional ownership trends. How do I buy shares of Replimune Group? Shares of REPL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Replimune Group own? Based on aggregate information from My MarketBeat watchlists, some other companies that Replimune Group investors own include Peabody Energy (BTU), Myovant Sciences (MYOV), Peabody Energy (BTUUQ), AVEO Pharmaceuticals (AVEO), Fate Therapeutics (FATE), Immunomedics (IMMU) and Pfizer (PFE). This page (NASDAQ:REPL) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredGet out of cash before the Fed's next meeting"How I 6X-ed my wife's 401K in 1 year" At the peak of the dot-com boom, a former hedge fund manager put all...Stansberry Research | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | SponsoredThis student turned $1,300 into $45,000 in just 4 Months!With the help of S.A.M. (my new AI-powered scanner) it's now easier than ever to find these unique trades... ...Monument Traders Alliance | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | Sponsored4 Steps to Survive the Coming Market CrashCracks threaten us with a widespread collapse unlike anything we've seen in our lifetime. During this prese...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Replimune Group, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Replimune Group With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free REPL Stock Alerts